[211At]NaAt / Riken, Osaka University - LARVOL DELTA

First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). (PubMed, J Nucl Med) - "Of the 5 patients who received 3.5 MBq/kg, complete response, partial response, and progressive disease were noted in 1 patient (20%) each, and SD was found in 2 patients (40%). Targeted α-therapy with [211At]NaAt was well tolerated and showed preliminary efficacy in patients with RAI-refractory DTC, supporting further clinical investigations."

First-in-human • Journal • P1 data • Dental Disorders • Hematological Disorders • Leukopenia • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Xerostomia • TG

A simplified feline phantom and Monte-Carlo simulation can be used to evaluate radiation exposure to veterinary staff during [211At]NaAt treatment. (PubMed, Front Vet Sci) - "The combined use of a 3D-printed phantom and numerical simulations demonstrated that occupational doses associated with [211At]NaAt treatment were within acceptable levels, and well below the occupational dose limits recommended by the ICRP, supporting the radiological safety of the procedure. The framework is readily applicable to other organs or animal species, thereby supporting the safe and feasible expansion of veterinary nuclear medicine."

Journal • Endocrine Disorders

A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: Alpha Fusion Inc.

New P1 trial • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Recent advances in theranostics and oncology PET: emerging radionuclides and targets. (PubMed, Ann Nucl Med) - "Alpha emitters, such as astatine (211At), are currently being evaluated in investigator-initiated clinical trials, with preliminary efficacy data reported for [211At]NaAt in patients with radioiodine-refractory thyroid cancer. Novel pan-tumor targeting agents, such as TROP-2, Nectin-4, LAT1, GPC-1, and EphA2, are also under development, and clinical translation of radioligand therapy is anticipated. These innovations in theranostics are expected to further broaden the scope of precision medicine in oncology."

Journal • Review • Oncology • Solid Tumor • Thyroid Gland Carcinoma • GPC1 • NECTIN4 • SSTR

Phase I investigator-initiated clinical trial of targeted alpha therapy using [211At]NaAt for refractory thyroid cancer (Alpha-T1 trial) (SNMMI 2025) - "This study demonstrated the feasibility and tolerability of targeted alpha therapy using [211At]NaAt in patients with refractory thyroid cancer. Further investigation is required in subsequent phase clinical trials to comprehensively assess its therapeutic efficacy."

Clinical • P1 data • Anorexia • Dental Disorders • Endocrine Cancer • Hematological Disorders • Leukopenia • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Xerostomia • TG